Genotype 5 or 6

    1. G5 or 6 naïve NON-CIRRHOTIC OR COMPENSATED CIRRHOTIC
      1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily for 12 weeks à 96% SVR12 [GENOTYPE 5] AND 100% SVR12 [GENOTYPE 6] (ASTRAL-1)
      2. Mavyret [Glecaprevir and Pibrentasvir 3-tablet coformulation] 3 tabs daily [with food] for 8 weeks à 100% SVR12 (SURVEYOR-2) AND 100% SVR12 (ENDURANCE-4) – NO CIRRHOSIS
      3. Mavyret [Glecaprevir and Pibrentasvir 3-tablet coformulation] 3 tabs daily [with food] for 12 weeks à 99% SVR12 (EXPEDITION-1) – COMPENSATED CIRRHOSIS

     

    1. G5 OR 6 prior treatment failures to PEG + RBV NON-CIRRHOTIC OR COMPENSATED CIRRHOTIC
      1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily for 12 weeks à 100% SVR12 (ASTRAL-1)
      2. Mavyret [Glecaprevir and Pibrentasvir 3-tablet coformulation] 3 tabs daily [with food] for 8 weeks à 100% SVR12 (PUOTI EASL 2017) – NO CIRRHOSIS
      3. Mavyret [Glecaprevir and Pibrentasvir 3-tablet coformulation] 3 tabs daily [with food] for 12 weeks à ?% SVR12– COMPENSATED CIRRHOSIS

     

    1. G5 OR 6 prior treatment failures to DAA-EXPERIENCED [INCLUDING NS5A-INHIBITORS] NON-CIRRHOTIC OR COMPENSATED CIRRHOTIC
      1. Vosevi [VEL/SOF/VOX daily fixed dose combination] 1 tab daily for 12 weeks à 100% SVR12 (POLARIS-1)

     

    SOF = Sofosbuvir [Solvaldi] – NS5B nucleotide analog polymerase inhibitor

    VEL = Velpatasvir [100 mg daily] – NS5A inhibitor

    Mavyret = Glecaprevir [300 mg] – NS3/4A protease inhibitor + Pibrentasvir [120 mg] –  NS5A inhibitor

Share on FacebookShare on Google+Share on LinkedInTweet about this on TwitterEmail this to someonePrint this page